Tyrosine Phosphatase (TP)

Product #



Biochem/physiol Actions


Add to Cart

B3686 BAY U6751 hydrate solid, ≥98% (HPLC) BAY W1807, the active metabolite of BAY R3401, inhibits muscle glycogen phosphorylase a and b. In gel-filtered liver extracts, racemic BAY U6751 (containing active BAY W1807) was tested for inhibition of phosphorylase in the glycogenolytic (in which only phosphorylase a is active). In liver extracts, BAY U6751 (0.9-36 μmol/L) inhibited glycogen synthesis by phosphorylase b (notwithstanding the inclusion of AMP), but not by phosphorylase a. Inhibition of phosphorylase-a-catalyzed glycogenolysis was partially relieved by AMP (500 μmol/L). BAY U6751 facilitated phosphorylase-a dephosphorylation. Isolated hepatocytes and perfused livers were tested for BAY R3401-induced changes in phosphorylase-a:b ratios and glycogenolytic output.
H2O: >8 mg/mL
B6060 BVT.948 ≥98% (HPLC), solid BVT.948 is a non-competitive inhibitor of protein tyrosine phosphatase (PTP). Enhances insulin signaling in cells and inhibits several cytochrome P450 isoforms in vitro.
DMSO: soluble18 mg/mL
H2O: insoluble
N9413 NSC 295642 ≥98% (HPLC), solid NSC 295642 is a potent inhibitor of cell migration. Cell migration is a basic biological process involved in a range of normal and pathological events, including wound healing, embryonic and tissue development, immune function and inflammation, angiogenesis and tumor metastasis. Therefore, cell migration can be adapted as an important biological tool to monitor several physiological processes as well as development of cancer. Accordingly, a potent inhibitor of cell migration, such as NSC 295642 can elucidate the intrinsic molecular mechanism of many biochemical events.
DMSO: >5 mg/mL
P0108 PRL-3 Inhibitor I ≥98% (HPLC), solid PRL-3 Inhibitor I is a rhodanine derivative with an IC50 value of 0.9 μM against phosphatase of regenerating liver-3 (PRL-3), a nonclassical protein tyrosine phosphatase that has recently been shown to be involved in cancer metastasis. PRL-3 Inhibitor I reduced the invasiveness of B16F10 melanoma cells in a cell based assay.
DMSO: >10 mg/mL
H2O: <2 mg/mL
P3075 Phenylarsine oxide ≥97%, powder Phenylarsine oxide inhibits internalization of cell surface receptors; inhibits tyrosine phosphatases, with no effect on tyrosine kinase. Metabolic poison.
DMSO: soluble50 mg/mL
P2850 Phosphatase Inhibitor Cocktail 1 DMSO solution    
P5726 Phosphatase Inhibitor Cocktail 2 aqueous solution (dark coloration may develop upon storage, which does not affect the activity) This mixture contains individual components with specific inhibitory properties. Sodium orthovanadate inhibits a number of ATPases, protein tyrosine phosphatases, and other phosphate-transferring enzymes. Sodium molybdate inhibits acid and phosphoprotein phosphatases. Sodium tartrate inhibits acid phosphatases. Imidazole inhibits alkaline phosphatases.
P0044   Phosphatase Inhibitor Cocktail 3 DMSO solution This mixture contains individual components with specific inhibitory properties. Cantharidin inhibits protein phosphatase 2A. (-)-p-Bromolevamisole oxalate inhibits L-isoforms of alkaline phosphatases. Calyculin A inhibits protein phosphatases 1 and 2A.
R2033 RK-682 ≥98% (HPLC) RK-682 is a specific and noncompetitive inhibitor of protein tyrosine phosphatase; It inhibited dephosphorylation activity of CD45 and VHR with IC50 54 and 2.0 microM and 4.5 microM against PTP1B.
Specific and noncompetitive inhibitor of protein tyrosine phosphatase.
DMSO, heptane and xylene: ≥8 mg/mL
S6508 Sodium orthovanadate ≥90% (titration) Inhibits ATPase, alkaline phosphatase and tyrosine phosphatase. Decavanadate, which is formed at acidic pH, inhibits inositol 1,4,5-trisphosphate (IP3)-induced Ca2+ release from endocrine cells and blocks IP3 binding to its receptor in brain tissue.
Sodium orthovandate suppresses the activation of p53-mediated apoptosis triggered in response to radiation. It reduces the detrimental effects of hematopoietic syndrome, hematopoiesis and delayed genotoxic effects of induced by total body irradiation of mice.24 In combination with menadione, orthovandate prevents the migration of detached human glioma cells in response to anti-cancer drugs.25
H2O: soluble
SML1299   TC-2153 ≥95% (HPLC) TC-2153 is a potent inhibitor of STEP (STriatal-Enriched protein tyrosine Phosphatase) that forms a reversible covalent bond with the catalytic cysteine in STEP. TC-2153 increases tyrosine phosphorylation of STEP substrates ERK1/2, Pyk2, and GluN2B in cell cultures. TC-2153 improves cognitive function in transgenic AD mice.
DMSO: soluble5 mg/mL, clear